P. Sharma

发表

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

E. Le Chatelier, N. Pons, N. Ajami, 2018, Science.

Abstract OT3-01-12: Phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer

C. Fabian, H. Yeh, Q. Khan, 2016 .

Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.

L. Carey, A. Bardia, H. Rugo, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Correlation of mammographic breast density with Ki-67 expression in benign breast epithelial cells obtained by random periareolar fine needle aspiration of high risk women.

B. Kimler, C. Fabian, Q. Khan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inherited Mutations in Cancer Susceptibility Genes Are Common Among Survivors of Breast Cancer Who Develop Therapy-Related Leukemia

P. Sharma, M. Hoffmann, P. Sharma, 2016 .

Last but not Least: Antibody-Drug Conjugates in Hormone Receptor-Positive Metastatic Breast Cancer.

P. Sharma, S. Stecklein, Priyanka Sharma, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Review of metastatic bladder cancer.

L. Pagliaro, P. Sharma, 2006, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy

C. Drake, W. Gerritsen, P. Sharma, 2014, Oncogene.

Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)

H. Linden, G. Hortobagyi, D. Tripathy, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer: Mulligan JM, Hill LA, Deharo S, et al (Queen's Univ Belfast, UK; et al) J Natl Cancer Inst 106:1-10, 2014§

P. Sharma, 2014 .

Radiotherapy Use and Locoregional Recurrence Rates on SWOG 1007, a US Cooperative Group Trial Enrolling Patients with Favorable-Risk Node-Positive Breast Cancer

R. Jagsi, L. Pusztai, E. Connolly, 2022, International Journal of Radiation Oncology, Biology, Physics.

1052PDNIVOLUMAB (N) (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH SUNITINIB (S) OR PAZOPANIB (P) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC).

E. Plimack, M. Voss, B. Rini, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1050OPHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC).

E. Plimack, M. Voss, B. Rini, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naïve castration-resistant prostate cancer (CRPC).

C. Logothetis, Y. Loriot, T. Beer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.

J. Blando, J. Allison, R. Wolff, 2019, Annals of Oncology.

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Shaughnessy, O. J., L. Carey, 2022 .